# US 2011/0035814 A1 · Cooperating oncogenes in cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0035814 A1
- Document ID: US20110035814A1
- Status: Published application
- Kind: A1
- Application number: 12/301,980
- Filed: 2007-05-23
- Published: 2011-02-10
- Earliest claimed: 2006-05-23
- Assignees: Cold Spring Harbor Laboratory
- Inventors: Lars Zender; Scott W. Lowe; Mona S. Spector; Wen Xue
- Web page: https://patentgrep.com/patent/US20110035814A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07K 14/4747: {Apoptosis related proteins}
- C07K 14/82: Translation products from oncogenes
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2510/04: Immortalised cells
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention provides methods of diagnosis, drug screening, and treatment based on the discovery that cIAP1 and Yap are co-amplified oncogenes that cooperate to contribute to oncogenesis and tumor maintenance.

## Claims

### Claim 1

A method of diagnosing liver cancer in a human patient, comprising:
providing a DNA sample from the liver of the patient, and
detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 11q22, wherein said amplification indicates that the patient has, or is susceptible of developing, liver cancer.

### Claim 2

The method of embodiment 1, wherein the nucleic acid sequence is from a cIAP1, cIAP2 or Yap gene.

### Claim 3

A method of selecting a cancer patient for treatment with an inhibitor of CDK, RAF, or MEK, comprising:
providing a DNA sample from the cancer tissue of the patient, and
detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 11q22, wherein said amplification indicates that the patient will be responsive to said treatment.

### Claim 4 (depends on 3)

The method of claim 3, wherein the nucleic acid sequence is from a cIAP1, cIAP2 or Yap gene.

### Claim 5

A method of selecting a liver cancer patient for treatment with an IAP inhibitor, comprising:
providing a DNA sample from the liver cancer tissue of the patient, and
detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 11q22, wherein said amplification indicates that the patient will be responsive to said treatment.

### Claim 6 (depends on 5)

The method of claim 5, wherein the nucleic acid sequence is from a cIAP1, cIAP2 or Yap gene.

### Claim 7

A method of inhibiting the growth of a cancer cell, comprising contacting the cell with an interfering RNA that inhibits the expression of Yap.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cancer cell is a liver cancer cell.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cancer cell is an epithelial cancer cell.

### Claim 10 (depends on 7)

The method of claim 7, wherein the cancer cell is a human cancer cell.

### Claim 11

A method of identifying a molecule for treating cancer, comprising:
providing a sample comprising Yap,
contacting said sample with a candidate molecule, and
detecting, in said sample, a decrease in the activity of said Yap, wherein said decrease indicates that the candidate molecule is useful for treating cancer.

### Claim 12

A mouse at least some of whose cells comprise a genome comprising a heterologous nucleic acid sequence comprising a Yap-coding sequence and an expression control sequence linked operatively thereto, wherein the mouse has cancer, or is more susceptible of developing cancer as compared to a control mouse not having said heterologous nucleic acid sequence.

### Claim 13 (depends on 12)

The mouse of claim 12, wherein the mouse is a transgenic mouse.

### Claim 14 (depends on 12)

The mouse of claim 12, wherein the mouse is a chimeric mouse some or all of whose hepatocytes comprise said genome.

### Claim 15 (depends on 12)

The mouse of claim 12, further comprising a second heterologous nucleic acid sequence comprising a cIAP1-coding sequence and a second expression control sequence linked operatively thereto.

### Claim 16 (depends on 12)

The mouse of claim 12, wherein the cells comprising said heterologous nucleic acid sequence further comprise a null mutation of a tumor suppressor gene.

### Claim 17 (depends on 16)

The mouse of claim 16, wherein the tumor suppressor gene is p53.

### Claim 18 (depends on 12)

The mouse of claim 12, wherein the cells comprising said heterologous nucleic acid sequence further comprise a shRNA against a tumor suppressor gene.

### Claim 19 (depends on 18)

The mouse of claim 18, wherein the tumor suppressor gene is p16 or p19.

### Claim 20 (depends on 12)

A method of identifying a molecule useful for treating cancer, comprising:
providing the mouse of claim 12, wherein the mouse has developed cancer, and
treating the mouse with a candidate molecule, wherein inhibition of the growth of said cancer indicates the candidate molecule is useful for treating cancer.

### Claim 21

A mammalian cell comprising (1) a first heterologous nucleic acid sequence comprising a Yap-coding sequence and a first expression control sequence linked operatively thereto, and (2) a second heterologous nucleic acid sequence comprising a cLAP1-coding sequence and a second expression control sequence linked operatively thereto.

### Claim 22 (depends on 21)

A method of identifying a molecule useful for treating cancer, comprising:
providing the cell of claim 21, and
contacting the cell with a candidate molecule, wherein inhibition of the growth of the cell indicates the candidate molecule is useful for treating cancer.

### Claim 23

A method of inhibiting the growth of a cancer cell, comprising contacting the cell with a first interfering RNA that inhibits the expression of Yap and an inhibitor that inhibits the activity of cIAP1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the inhibitor is an interfering RNA that inhibits the expression of cIAP1.

### Claim 25 (depends on 23)

The method of claim 23, wherein the inhibitor is a SMAC homolog.

### Claim 26 (depends on 23)

The method of claim 23, wherein the cancer cell is a human cancer cell.

### Claim 27

A method of treating cancer, comprising administering to a cancer patient an inhibitor of cIAP1 or cIAP2 and an inhibitor of MEK or CDK.

### Claim 28

A method of treating cancer, comprising administering to a cancer patient a shRNA against Yap and an inhibitor of MEK or CDK.

### Claim 29

A method of treating cancer, comprising administering to a cancer patient an inhibitor of cIAP1 and a shRNA against Yap.

### Claim 30

A method of treating cancer, comprising administering to a cancer patient (1) an inhibitor of cIAP1 or CIAP2, or a shRNA against Yap, and (2) a chemotherapy agent.

### Claim 31 (depends on 27, 28, 29, 30)

The method of any of claims 27-30, wherein the cancer tissue of said patient comprises amplification of a nucleic acid sequence in chromosomal region 11q22.
